Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy

Inclusion Criteria: * Aged 18 to 80 years, regardless of gender. * Histologically confirmed gastric cancer or gastroesophageal junction (GEJ) cancer that has received neoadjuvant therapy, with pathology confirming it is predominantly adenocarcinoma. For GEJ cancer, only Siewert Type III and Siewert Type II cases that do not require combined thoracotomy are eligible. * Tumor stage confirmed as cStage III, suitable for curative R0 resection, as determined by an evaluation by a gastrointestinal surgeon and a radiologic technician prior to enrollment. The patient agrees to undergo robotic-assisted radical surgery, and the surgeon judges there are no surgical contraindications. * Expected survival of ≥6 months. * Measurable tumor lesions as defined by RECIST v1.1 criteria (see Attachment 1). * Preoperative ECOG performance status score (see Attachment 2) of 0 or 1. * Good cardiac function, capable of undergoing a curative resection. If there are clinical indications, patients with underlying ischemic, valvular heart disease, or other serious heart conditions should undergo preoperative assessment by a cardiologist. * Normal major organ function, with the following laboratory criteria: * Absolute neutrophil count (ANC) ≥ 1.2 x 10\^9/L in the absence of granulocyte colony-stimulating factor use within the past 14 days. * Platelet count ≥ 100 x 10\^9/L in the absence of blood transfusion within the past 14 days. * Hemoglobin \> 8 g/dL in the absence of blood transfusion or erythropo…